Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine - Wikidata - wikimedia - TriplyDB

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine

http://www.wikidata.org/entity/Q28631811

about

Possibilities and challenges for developing a successful vaccine for leishmaniasis Post-Genomics and Vaccine Improvement for Leishmania Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate.HisAK70: progress towards a vaccine against different forms of leishmaniosis.Pharmacodynamics and Biodistribution of Single-Dose Liposomal Amphotericin B at Different Stages of Experimental Visceral Leishmaniasis.DNA vaccine against visceral leishmaniasis: a promising approach for prevention and control.Histopathological and immunohistochemical characterisation of hepatic granulomas in Leishmania donovani-infected BALB/c mice: a time-course study.Alternative to Chemotherapy-The Unmet Demand against Leishmaniasis.

P2860

Q26749758-D17AC6FC-7C1F-442A-80EF-66DBEB8DC6C2 Q26752532-20BE2EFF-ADC4-46EE-BF64-5B1ECAB213D6 Q30401521-D482704F-01D6-4649-8D05-1762FFC5208C Q35960819-5EB25F29-FEC0-4BE7-9466-7A7C4F345E7A Q36361604-0440348E-2BD3-471A-A76E-5234DC8E72A1 Q38718391-3F05F5C8-86D0-48C4-8063-BF5F743C891A Q38786910-E2CD0946-26BC-4364-9FAC-411DAB8E46B5 Q49428820-498B12EE-D9C4-4277-922E-2A06124A298E Q50130388-9DF52840-515A-4241-8AFA-72645A83D8D8

P2860

Preclinical safety and tolerability of a repeatedly administered human leishmaniasis DNA vaccine

http://www.wikidata.org/entity/Q28631811

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@ast

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@en

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@nl

type

label

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@ast

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@en

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@nl

prefLabel

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@ast

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@en

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@nl

P1433

Q28631811-E31067F3-15D9-4AAF-B1E4-86ACA65A4692

P1476

Q28631811-75C15E0D-1DA0-4F40-8034-B4DD2F7C75DD

P2093

Q28631811-138382F0-9C95-4854-8357-EA6CF55E6E97

Q28631811-5B687631-C899-4410-8F24-1FEF6271DC9C

Q28631811-6701F975-4159-4391-95F3-6ABA8905BD31

Q28631811-743A7D44-9C2C-49B5-A90A-408FEE11555C

Q28631811-95D5B337-A845-4D10-879D-76E7887CCC8F

Q28631811-9F64C74F-A5FD-4708-BDF2-73D8AD81F972

Q28631811-CD4E45A5-BE7A-4BAD-BA54-97B16454B442

Q28631811-E2C34AE7-F66A-4A55-8FF8-CE4644F1690C

P2860

Q28631811-04422F99-9081-4571-82F1-925EBB1D7525

Q28631811-0D7D2E1D-DF9D-42F3-B787-108005D5A8CA

Q28631811-16972D60-6934-49C0-AC6A-8D5185735453

Q28631811-1EF89D62-C431-4B84-B746-5BEE73D4F34D

Q28631811-253FCB23-3EEC-457D-83D8-FA3E913B5AEA

Q28631811-3065BFD7-D3D0-4D79-8664-5B28048B5940

Q28631811-33520937-E5A3-46B7-A1F7-700DD6DE6FED

Q28631811-35F348DD-924E-4A28-AAA8-480935976B4C

Q28631811-3B3274C8-FFA4-465D-A7F1-495F20D3E6EC

Q28631811-44FE7662-AD85-4950-9433-4C9B59A52838

P2888

Q28631811-56EC5B6F-432B-466D-A5EB-EBFBC8442C31

P304

Q28631811-FC6B5966-FA3F-4FDD-B497-96EF1CAD9872

P31

Q28631811-823E79B0-E605-47EE-BFB6-600DFADC057D

P3181

Q28631811-B36C6858-6D72-4727-9E63-06D54AA4F602

P356

Q28631811-1CF3DB0F-5C76-481A-873E-FD2B71BFDFF4

P407

Q28631811-44AAAB80-0FCE-4858-ABD2-9942C4D54D44

P433

Q28631811-239A21A9-5007-4833-9CE9-50655B99DFC2

P478

Q28631811-14FE4B80-B305-43AC-99B0-3A99EB535840

P50

Q28631811-20236CE1-5C1E-407E-9999-ED937924868C

Q28631811-74AD3A8F-91B7-41F8-A7E7-0920624F0EE1

P577

Q28631811-01716A31-0106-40A8-BD5D-328C7CD6D141

P5875

Q28631811-4CB6E26E-6839-4F63-ADAD-4163D7824301

P6179

Q28631811-8FC541B7-A93A-4F9A-95A5-31A69130C65B

P698

Q28631811-E45259A7-04E4-4F52-9E1E-E5CE56420542

P932

Q28631811-6399A25B-CC97-4F0F-A0EE-1A934A8A0BA1

P3181

P356

P1433

P1476

Preclinical safety and tolerab ...... uman leishmaniasis DNA vaccine

@en

P2093

A Endmann

http://www.w3.org/2001/XMLSchema#string

A Winkler

http://www.w3.org/2001/XMLSchema#string

C Hock

http://www.w3.org/2001/XMLSchema#string

D Oswald

http://www.w3.org/2001/XMLSchema#string

K Seifert

http://www.w3.org/2001/XMLSchema#string

M Schroff

http://www.w3.org/2001/XMLSchema#string

O Riede

http://www.w3.org/2001/XMLSchema#string

S L Croft

http://www.w3.org/2001/XMLSchema#string

P2860

Leishmaniasis worldwide and global estimates of its incidence

Toxicological Safety Evaluation of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar Despite Differing Plasmid Backbones or Gene-Inserts

Biodistribution of DNA Plasmid Vaccines against HIV-1, Ebola, Severe Acute Respiratory Syndrome, or West Nile Virus Is Similar, without Integration, despite Differing Plasmid Backbones or Gene Inserts

Traitors of the immune system-enhancing antibodies in HIV infection: their possible implication in HIV vaccine development

Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin.

Nonclinical biodistribution, integration, and toxicology evaluations of an H5N1 pandemic influenza plasmid DNA vaccine formulated with Vaxfectin®.

Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine

Marker-free plasmids for biotechnological applications - implications and perspectives.

Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes

Differential Regulation of the Immune Response in the Spleen and Liver of Mice Infected with Leishmania donovani.

P2888

P304

628-635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1685200

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/GT.2015.35

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

Francisco J. Salguero

P577

2015-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274964438

http://www.w3.org/2001/XMLSchema#string

P6179

1028860827

http://www.w3.org/2001/XMLSchema#string

P698

25871827

http://www.w3.org/2001/XMLSchema#string

P932

4530203

http://www.w3.org/2001/XMLSchema#string